Is Elevance Health (ELV) Fairly Valued On Its Conference Outlook Reassurance?

Elevance Health (ELV) used its appearance at the Wells Fargo 21st Annual Healthcare Conference on 10 September 2026 to reinforce its earnings outlook and cost discipline, keeping the recent valuation conversation very much alive.

Recent trading has been mildly soft, with the share price down 0.8% on the day and 1.9% over the past week. Even so, Elevance Health still carries a 16.0% year to date share price return and a 33.6% 1 year total shareholder return, indicating that momentum has cooled at the margin rather than reversed.

Scan how Elevance Health compares with other insurers and healthcare groups on valuation and quality by reviewing our curated list of list of solid balance sheet and fundamentals (23 results).

Elevance Health is reinforcing the story of a large, profitable insurer, yet the recent cooling in the share price raises a sharper question. Are you now paying a fair multiple for that strength, or a premium that is hard to justify?

Most Popular Narrative: 8% Undervalued

At a last close of $410.95 against a narrative fair value of $449.10 using a 7.23% discount rate, Elevance Health screens as modestly undervalued on this framework, which keeps the focus squarely on whether future margins can actually match expectations.

Demographic shifts, notably the aging U.S. population and increasing chronic disease prevalence, underpin long-term growth opportunities in Medicare Advantage and Medicaid. Elevance's disciplined approach to pricing and rate negotiations, combined with proactive engagement with state partners, is expected to drive sustainable revenue growth and margin recovery in these government-backed segments.

See why 112 investors see Elevance Health as 8% undervalued.

Result: Fair Value of $449.10 (UNDERVALUED)

Still, the story around Elevance Health can unravel quickly if Medicaid utilization stays elevated or if regulatory changes hit pricing and membership harder than analysts anticipate.

Find out about the key risks to this Elevance Health narrative.

Next Steps

With sentiment on Elevance Health tilted toward cautious optimism, it helps to move quickly and pressure test the thesis against hard numbers yourself. To see what others view as the key positives before making a call, review the 4 key rewards.

Looking for more investment ideas beyond Elevance Health?

If Elevance Health has sharpened your thinking, do not stop here. Let the Simply Wall St screener surface fresh opportunities that match your style before others move first.

• Target value opportunities that pair quality with attractive pricing by scanning our curated set of 35 high quality undervalued stocks.
• Prioritise resilience and sleep-better-at-night holdings by reviewing a focused group of 30 resilient stocks with low risk scores.
• Hunt for future standouts that still fly under the radar using our handpicked 16 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com